OLYMPUS
14.9.2022 03:01:37 CEST | Business Wire | Press release
Olympus Corporation (“Olympus” - Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced the launch of VISERA ELITE III, its newest surgical visualization platform that addresses the needs of healthcare professionals (HCPs) for endoscopic procedures across multiple medical disciplines. VISERA ELITE III offers various imaging functions, all supported in one system enabling minimally invasive therapies such as Laparoscopic Colectomy and Laparoscopic Cholecystectomy. Future software upgrades will advance surgical imaging technology and allow for individual configurations that facilitate seamless support of various surgical applications leading to a reduction in investment costs. VISERA ELITE III will be available in Europe, Middle East and Africa (EMEA), parts of Asia, Oceania, and Japan in September 2022 or later.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005632/en/
Surgical visualization platform VISERA ELITE III (Photo: Business Wire)
“With VISERA ELITE III, we provide a best-in-class surgical visualization platform designed for multiple medical specialties and configurations, allowing HCPs to fully focus on the patient during surgery. By incorporating the technologies of its predecessors VISERA ELITE II and VISERA 4K UHD into one platform, VISERA ELITE III enhances the quality of endoscopic surgery, contributes to improved efficiency in the operating room, and hereby elevates the standard of care,” said Kanichi Matsumoto, Global Head of Surgical Endoscopy at Olympus.
One System for All
VISERA ELITE III system integrates the 3D and infrared1 imaging functions from VISERA ELITE II, and the 4K imaging function from VISERA 4K UHD system. It also supports fluorescence guided surgery as well as NBI2, a unique observation mode developed by Olympus. By providing surgeons with multiple observation modes, the all-in-one system supports standardization and increases efficiency in the operating room. Users can also set up customized departmental profiles on VISERA ELITE III for different medical disciplines such as general surgery, urology, gynecology, ENT surgery and more. The platform is compatible with existing endoscopes from VISERA ELITE II.
Innovation That Grows with Need
The platform allows software upgrades to add new surgical imaging functions as needed. Switching entire surgical visualization systems to access the latest technology is no longer necessary, which not only sets a new standard and provides a high degree of flexibility, but also makes VISERA ELITE III a future-proof investment.
Improved Image Quality for More Focus
VISERA ELITE III system comes with a focus adjust mode during 4K surgical observation and is equipped with the EDOF (Extended Depth of Field) function that allows precise endoscopic observations through continuous broad focus and seamless magnification. In addition, it provides the C-AF (Continuous Auto Focus) capability that automatically adjusts focus in accordance with the movement of the camera head and endoscope. This facilitates clearer image capture, both up close and at a greater distance, so that HCPs experience less stress during surgery, allowing them to concentrate on the patient and the procedure's outcome.
VISERA ELITE III combines Sony Corporation’s state-of-the-art digital imaging technologies with the expertise and experience in medical product development that Olympus has accumulated over decades as a leading endoscope manufacturer and addresses the growing needs of hospitals as recognized through extensive exchange with customers.
In developing VISERA ELITE III, Sony Olympus Medical Solutions, a joint venture company of Sony and Olympus, optimized each technology and image processing function specifically for medical applications to create the most advanced, open, and versatile surgical visualization platform Olympus has ever brought to market.
About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety.
In its Endoscopic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance the quality of life for patients. Starting with the world’s first gastrocamera in 1950, Olympus’ Endoscopic Solutions portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, as well as customer solutions and medical services. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.
Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.
______________________________
1 Infrared imaging is a special light observation function for observing the fluorescence generated by administering a fluorescent agent called indocyanine green (ICG) and by applying near-infrared light (light with a wavelength of 700-780 nm).
2 NBI (Narrow Band Imaging) is an imaging technique for examining features such as the small blood vessels in mucosa and the surface patterns. NBI highlights tissue by illuminating it with two narrow bands (wavelengths) of light that are absorbed by the hemoglobin in blood.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005632/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
